LITHION-RECYCLING
25.1.2022 12:02:11 CET | Business Wire | Press release
Lithion Recycling, Inc. (“Lithion”) is proud to announce it has reached an agreement with IS Dongseo Company Ltd (“ISD”), a Korea-based leading ESG company with an environmental business segment, for an exclusive business right for the use of its lithium-ion battery recycling technology on the Korean market.
This partnership is the first of a series that Lithion aims to conclude in upcoming years for the use of its cutting-edge, eco-friendly technology on world markets. It will allow ISD to offer an environmentally friendly and cost-effective recycling solution to close the loop on battery materials in Korea. IS Dongseo plans to start building its first Korean facility capable of processing about 7,500 tons of waste batteries per year (or the equivalent of approximately 20,000 electric car batteries), this year. This first phase will be followed by a second one, with the construction of a hydrometallurgy plant based on Lithion’s technology, allowing ISD to supply over 15,000 tons of battery-grade materials per year.
“We are extremely proud to announce our first strategic partnership and licensing agreement with such a strong partner as IS Dongseo, an experienced battery recycling plant operator firmly rooted in the Korean market. This exclusive agreement confirms the high potential of the technology and the business model we have been developing over the years and will enable the use of our “Spoke” and “Hub” technologies on a major market for the lithium-ion battery sector. Our licensing strategy will ensure a rapid deployment of our technology globally since we are leveraging local and regional forces rather than developing and operating all plants by ourselves. This is a very exciting milestone in our quest for providing sustainable, cost-effective and locally-adapted solutions for recycling lithium-ion batteries around the globe.”
– Benoit Couture, President and CEO of Lithion Recycling, Inc.
“Recognizing that Lithion has the best battery recycling technology and following a thorough technology diligence, we are delighted to partner with them to secure full competitiveness in the battery and battery waste recycling. Korea is home base to many important and dynamic actors in the lithium-ion battery and battery materials supply chain. As these companies are rapidly expanding in Asia, in the United States and in Europe, our partnership with Lithion opens up tremendous global growth opportunities for both of us.”
– Jeon, Hyung Joon, Battery Recycle Business Director of IS Dongseo Company Ltd
The need for lithium-ion battery recycling is growing exponentially and Lithion’s commercial plants have scalable capacities to adapt to market size. Because the volume of batteries at the end of their life is spread worldwide, Lithion is planning large-scale international deployment, which will be achieved by granting licenses to strategic operating partners. The goal is to commission over 25 battery recycling plants based on Lithion’s technology in the next 15 years in cities and jurisdictions where the need is most urgent.
This is the second major announcement for Lithion in two days. On January 24, the company announced it has reached financial close on a significant first tranche of a Series A financing for up to $125 million that will be invested in the construction of its first lithium-ion battery recycling plant and a state-of-the-art Technology Development Center in Quebec, Canada as well as bringing its hydrometallurgy technology plant to breaking ground.
About Lithion Recycling, Inc.
Lithion has developed an efficient and cost-effective process to recover strategic materials from end-of-life and product waste of lithium-ion batteries. Lithion’s process allows up to 95% of battery components to be recovered and treated so that they can be reused by battery manufacturers, enabling to close the lifecycle in batteries. This technology accelerates the transition to green energy and helps meet decarbonization targets by reducing pressure on natural resource extraction. This year, Lithion launches its first commercial recycling operations, drawing on data from a highly successful Quebec industrial-scale demonstration plant commissioned in January 2020. Its goal is worldwide deployment, through licensing agreements, with a target of 20 recycling plants on a world scale. For more information, please visit: https://www.lithionrecycling.com/
About IS Dongseo Company Ltd
Established in 1975, IS Dongseo has been a leading construction group in South Korea. Over 1,000 employees and executives in the construction and manufacturing divisions are maximizing the synergy by the deployment of cutting-edge technology and the cooperative initiatives in each field. IS Dongseo is expanding in the global market by diversifying its business through entry into environment business, maritime transport and other sectors. Aligned with industry leading affiliates like Insun and KR energy and others, IS Dongseo is expanding its business territory into recycling business dealing with ESG issues. For more information, please visit: http://isdongseo.co.kr/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220125005335/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom